Navigation Links
Cequent Names Ted Hibben Chief Business Officer
Date:1/12/2009

CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Ted Hibben has joined the company as chief business officer. Mr. Hibben comes to Cequent from Coley Pharmaceutical Group, where he was most recently vice president of business development and alliance management and played a key role in the company's $233 million acquisition by Pfizer in 2008. Coley was a publicly traded biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, asthma, infectious diseases, and autoimmune diseases.

"Strategic partners have been key to Cequent's success to date and will become even more important as we continue to move our tkRNAi technology from the laboratory into clinical development against multiple diseases. Ted brings to Cequent a wealth of experience orchestrating a full range of strategic collaborations with leading pharmaceutical and biotech companies - from drug discovery, research, and clinical-development partnerships to licensing agreements," said Cequent President and CEO, Peter Parker. "Beyond his role in the Pfizer acquisition, Ted's recent track record includes closing nearly a dozen alliances totaling $750 million of itemized pre-commercial development milestones with companies like Novartis, GSK, and Merck."

Regarding Mr. Hibben's role at Cequent, Mr. Parker said, "Ted will focus on external partnering activities in three major areas. On our inflammatory bowel disease (IBD) program, he will look for partner(s) to further develop one or more of the 11 targets we are working on for Crohn's disease and ulcerative colitis; he will also seek to partner our CEQ508 candidate for FAP, slated for a Phase I clinical trial in 2009. FAP (familial adenomatous polyposis) is an inherited precursor to colon cancer that causes hundreds of polyps to form in the colon. In addition, Ted will interact with companies that would like to license our technology to deliver therapeutic RNAi for novel metabolic, oncology, or other targets."

Previously, Mr. Hibben served as a senior executive and a corporate and business development consultant for public and private biopharmaceutical companies, including, among others: Centagenetix, Inc., in conjunction with its merger into Elixir Pharmaceuticals, Inc.; Pericor Science, Inc., where he led strategic planning, business operations, and product development for this start-up advancing a novel epithelial drug-delivery technology; and Ontogeny, Inc. (now Curis, Inc.), where he guided Ontogeny's merger with Reprogenesis and Creative Biomolecules. Mr. Hibben has an MBA from Harvard Business School and a bachelor's degree from Dartmouth College.

About Cequent Pharmaceuticals, Inc. (www.cequentpharma.com)

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.


'/>"/>
SOURCE Cequent Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
4. Clarus Ventures Names Two New Partners
5. Xceleron Names Michael Butler as President & CEO
6. Genome Technology Names 2008 Tomorrows PIs
7. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
8. USP Names Matthew Heyman Vice President of External Affairs and Strategic Integration
9. LCA-Vision Names Michael J. Celebrezze CFO
10. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply
11. Great Basin Scientific, Inc. Names Laurence Rea as Vice President of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... instrument solutions, announces the appointment of Steven F. McAllister as Executive Vice President ... experience in both the U.S. and international markets. Beginning his career at Howmedica, ...
(Date:1/24/2017)... ... January 24, 2017 , ... Nor-Tech’s leading-edge ... cluster with user-friendly bootable Intel KNL. , Currently Cal Tech researchers are ... demo cluster. The demo cluster is a no-cost, no-strings opportunity for current and ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... Oklahoma City ... the newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... with the dynamic team at CJBC and thrilled that they have decided to implement ...
(Date:1/24/2017)... Jan. 23, 2017  Today, the Fisher Center for ... funded an important study that could lead to the ... of Alzheimer,s disease. This groundbreaking research was conducted by ... by Nobel Laureate Dr. Paul Greengard , in ... Fisher Center scientists have linked a mutation ...
Breaking Biology Technology:
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
Breaking Biology News(10 mins):